Supraspinatus TendonitisTECARNCT07794033
Effect of TECAR on Supraspinatus Tendon Thickness in Supraspinatus Tendinitis
A study testing TECAR therapy and conventional physiotherapy in people with Supraspinatus Tendonitis, run by Cairo University at 1 site in Egypt.
Trial summary
Is the TECAR therapy effective on supraspinatus tendon thickness, sub acromial space, pain intensity , shoulder range of motion, muscle strength ( supraspinatus and middle fiber of deltoid) and functional disabilities in patients with supraspinatus tendinitis? Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Supraspinatus Tendonitis
- What is being tested?
- TECAR therapy and conventional physiotherapy
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 50 participants
- Where
- 1 siteEgypt
- Study dates
- 10 Sep 2026to 10 Apr 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Fifty patients with chronic supraspinatus tendinitis on the dominant side.
- Patients with age range from 18 to 65 years old from both genders.
- Patients reporting positive empty can test.
- patients reporting pain with resisted isometric abduction.
- Patients experiencing shoulder pain for at least 4 weeks.
- patients reporting pain with active shoulder elevation in the scapular plane.
Who cannot join
- Patients with shoulder surgery or trauma in the past 6 months will be excluded.
- Patients with full-thickness rotator cuff tears, fractures, or severe osteoarthritis will be excluded.
- Patients with systemic diseases affecting tendon healing (e.g., uncontrolled diabetes, rheumatoid arthritis) will be excluded.
- Patients who were pregnant or breastfeeding will be excluded.
- Patients currently receiving other shoulder therapies that could affect outcomes will be excluded.
- Patients with frozen shoulder will be excluded.
- Patients with glenohumeral or acromioclavicular arthritis will be excluded.
- Patients with an implanted pacemaker will be excluded.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Egypt1 site
Shireen Mohamed Mahmoud
Giza, 11432
Shireen M Mahmoud, B.SC, 01121768657, shireenmohamed155@icloud.com
Shireen Mahmoud, B.SC, 01121768657, shireenmohamed155@icloud.com
About this study
Official title: Effect of Transfer Energy Capacitive and Resistive Therapy on Supraspinatus Tendon Thickness and Subacromial Space in Supraspinatus Tendinitis
Is the TECAR therapy effective on supraspinatus tendon thickness, sub acromial space, pain intensity , shoulder range of motion, muscle strength ( supraspinatus and middle fiber of deltoid) and functional disabilities in patients with supraspinatus tendinitis?
Read the detailed description
Supraspinatus tendinitis is a common disorder of the rotator cuff characterized by inflammation and degeneration of the supraspinatus tendon, typically resulting from repetitive overhead activities, mechanical impingement beneath the acromion, or age-related degenerative changes. This condition often leads to shoulder pain, reduced range of motion, and functional impairment during arm elevation and overhead movements. Recently, Studies demonstrated that the addition of TECAR therapy to a standard physiotherapy regimen improves shoulder pain, disability, and passive range of motion in patients with adhesive capsulitis, supporting the use of TECAR as an effective modality in shoulder musculoskeletal rehabilitation.
- Conditions
- Supraspinatus Tendonitis
- Being tested
- TECAR therapy, conventional physiotherapy
- Keywords
- TECAR, supraspinatus tendonitis, sub acromial space
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
TECAR therapyOther
Patients will be in a comfortable side-lying with treated shoulder uppermost and clean the area over the affected shoulder, apply coupling medium and then apply Capacitive mode to shoulder muscles for 10 minutes and Resistive mode for another 10 minutes.
conventional physiotherapyOther
Patients will receive conventional physiotherapy (range of motion exercises, stretching exercises, strengthening exercises, and scapular stabilization exercises).
| Study group | Role | What they receive |
|---|---|---|
| TECAR therapy | Experimental | 25 Patients will receive TECAR therapy and conventional physiotherapy three times per week for four weeks Receives: Other: TECAR therapy; Other: conventional physiotherapy |
| conventional physiotherapy | Active comparator | 25 patients will receive conventional physiotherapy only three times per week for four weeks Receives: Other: conventional physiotherapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
tendon thickness of supraspinatus muscle
tendon thickness of supraspinatus muscle will be measured by ultrasonography
Measured: up to four weeks
Sub acromial space
Sub acromial space will be assessed using Ultrasonography.
Measured: up to four weeks
Secondary outcomes (4)
pain intensity
visual analogue scale (VAS) will be used to asses pain intensity which patient will be instructed to put point on line from no pain to tolerable pain. The scale consists of a line, usually 10 cm long, ranging from no pain or discomfort (zero) , to the worst pain that could possibly feel (10).
Measured: up to four weeks
Shoulder Range of motion
Shoulder range of motion will be assessed using an electro goniometer.
Measured: up to four weeks
Muscle strength
Muscle strength will be assessed using a handheld dynamometer (Lafayette Manual Muscle Tester).
Measured: up to four weeks
Shoulder functional disability
Shoulder functional disability will be assessed using the Disabilities of the Arm, Shoulder and Hand (DASH). Quick DASH questionnaire is an 11-item patient-reported outcome measure designed to evaluate physical function and symptoms in individuals with upper extremity disorders. Each item is scored on a 5-point Likert scale ranging from "no difficulty" to "unable," and the total score is calculated by transforming the mean of the responses into a 0-100 scale, where higher scores indicate greater disability.
Measured: up to four weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 Aug 2026
- Study start10 Sep 2026 (estimated)
- Primary completion10 Apr 2027 (estimated)
- Study completion10 Apr 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Supraspinatus TendonitisStudies of the same condition, open and under way.
- More trials run by Cairo UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Cairo University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Shireen Mohamed Mahmoud, Cairo University
- Investigators
- Alshaymaa Sh Abd El-Azeim, PHD, Study director, Assistant professor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07794033
- Sponsor's protocol ID
- P.T.REC/012/006619
- Acronym
- TECAR
- Status last verified
- Aug 2026
- First submitted
- 26 Aug 2026
- Last updated
- 1 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: we will share the results of the trial 1-Supraspinatus tendon thickness 2-Subacromial space 3-Pain intensity 4-Shoulder range of motion 5-Muscle strength 6-Shoulder functional disability
Study at a glance
From the registry record, last updated by the sponsor on 1 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Transfer Energy Capacitive and Resistive Therapy on Supraspinatus Tendon Thickness and Subacromial Space in Supraspinatus Tendinitis
- ClinicalTrials.gov ID
- NCT07794033
- Acronym / sponsor ID
- TECAR / P.T.REC/012/006619
- Conditions
- Supraspinatus Tendonitis
- Keywords
- TECAR, supraspinatus tendonitis, sub acromial space
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- Cairo UniversityUniversity, hospital or other
- Study start
- 10 Sep 2026 (estimated)
- Primary completion
- 10 Apr 2027 (estimated)
- Study completion
- 10 Apr 2027 (estimated)
- First posted
- 31 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Is the TECAR therapy effective on supraspinatus tendon thickness, sub acromial space, pain intensity , shoulder range of motion, muscle strength ( supraspinatus and middle fiber of deltoid) and functional disabilities in patients with supraspinatus tendinitis?
Detailed description
Supraspinatus tendinitis is a common disorder of the rotator cuff characterized by inflammation and degeneration of the supraspinatus tendon, typically resulting from repetitive overhead activities, mechanical impingement beneath the acromion, or age-related degenerative changes. This condition often leads to shoulder pain, reduced range of motion, and functional impairment during arm elevation and overhead movements. Recently, Studies demonstrated that the addition of TECAR therapy to a standard physiotherapy regimen improves shoulder pain, disability, and passive range of motion in patients with adhesive capsulitis, supporting the use of TECAR as an effective modality in shoulder musculoskeletal rehabilitation.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| TECAR therapy | Experimental | Other: TECAR therapy, Other: conventional physiotherapy25 Patients will receive TECAR therapy and conventional physiotherapy three times per week for four weeks |
| conventional physiotherapy | Active comparator | Other: conventional physiotherapy25 patients will receive conventional physiotherapy only three times per week for four weeks |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Fifty patients with chronic supraspinatus tendinitis on the dominant side.
- Patients with age range from 18 to 65 years old from both genders.
- Patients reporting positive empty can test.
- patients reporting pain with resisted isometric abduction.
- Patients experiencing shoulder pain for at least 4 weeks.
Key exclusion criteria (8 listed)
- Patients with shoulder surgery or trauma in the past 6 months will be excluded.
- Patients with full-thickness rotator cuff tears, fractures, or severe osteoarthritis will be excluded.
- Patients with systemic diseases affecting tendon healing (e.g., uncontrolled diabetes, rheumatoid arthritis) will be excluded.
- Patients who were pregnant or breastfeeding will be excluded.
- Patients currently receiving other shoulder therapies that could affect outcomes will be excluded.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| TECAR therapyPatients will be in a comfortable side-lying with treated shoulder uppermost and clean the area over the affected shoulder, apply coupling medium and then apply Capacitive mode to shoulder muscles for 10 minutes and Resistive mode for another 10 minutes. | Other | TECAR therapy |
| conventional physiotherapyPatients will receive conventional physiotherapy (range of motion exercises, stretching exercises, strengthening exercises, and scapular stabilization exercises). | Other | TECAR therapy, conventional physiotherapy |
Primary outcome
tendon thickness of supraspinatus muscle
Time frame: up to four weeks
tendon thickness of supraspinatus muscle will be measured by ultrasonography
Sub acromial space
Time frame: up to four weeks
Sub acromial space will be assessed using Ultrasonography.
4 secondary outcomes
pain intensity
Time frame: up to four weeks
Shoulder Range of motion
Time frame: up to four weeks
Muscle strength
Time frame: up to four weeks
Shoulder functional disability
Time frame: up to four weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Sep 2026.
- Individual participant dataSharing planned: Yes. we will share the results of the trial 1-Supraspinatus tendon thickness 2-Subacromial space 3-Pain intensity 4-Shoulder range of motion 5-Muscle strength 6-Shoulder functional disability
Related trials for Supraspinatus Tendonitis
Recruiting
Effects of Cervicothoracic Mobilization in Patients With Supraspinatus Tendinitis
Rotator Cuff Tendonitis
Recruiting
HILT vs ESWT in Supraspinatus Tendinitis
Supraspinatus Tendinitis
Recruiting
Anatomical Evaluation of Supraspinatus Through Ultrasonography and Biomechanical Measurements Following Blood Flow Restriction Therapy and Eccentric Exercise in Patients of Supraspinatus Tendinitis.
Supraspinatus Tendinitis
Recruiting
Reverse Fly Exercise On Supraspinatus Tendinitis In Patients Receiving Aromatase Inhibitors Therapy After Mastectomy
Mastectomy, Aromatase Inhibitors Therapy
Active, not recruiting
Anatomical Evaluation of Supraspinatus Through Ultrasonography and Biomechanical Measurements Following Different Combinations of Physical Therapies in Patients of Supraspinatus Tendinitis
Supraspinatus Tendinitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Alshaymaa Sh Abd El-Azeim, PHD study director
Assistant professor
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing TECAR therapy and conventional physiotherapy in people with Supraspinatus Tendonitis, run by Cairo University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 1 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Shireen M Mahmoud, Demonstrator (01121768657, shireenmohamed155@icloud.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
tendon thickness of supraspinatus muscle (time frame: up to four weeks). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Sep 2026.